about
sameAs
Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protectionSystemic causes of cholestasisIn vitro hepatic trans-differentiation of human mesenchymal stem cells using sera from congestive/ischemic liver during cardiac failureLiver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) programBilirubin as a prognostic marker in patients with pulmonary arterial hypertension.Acute-on-chronic liver failure due to thiamazole in a patient with hyperthyroidism and trilogy of Fallot: case report.Portal vein pulsatility index is a more important indicator than congestion index in the clinical evaluation of right heart functionLiver dysfunction assessed by model for end-stage liver disease excluding INR (MELD-XI) scoring system predicts adverse prognosis in heart failureBeta-blockers Associated with a Mortality Benefit in Patients with Systolic Dysfunction and Elevated Serum Bilirubin.Hepatic congestion leads to fibrosis: findings in a newly developed murine model.Hepatic dysfunction in hyperthyroidismPharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study.Evidence of Mild Liver Dysfunction Identifies Stable Heart Failure Outpatients with Reversible Renal Dysfunction.Liver abnormalities in cardiac diseases and heart failureLow Cardiac Output Leads Hepatic Fibrosis in Right Heart Failure Model Rats.Liver dysfunction as a predictor of outcomes in patients with advanced heart failure requiring ventricular assist device support: Use of the Model of End-stage Liver Disease (MELD) and MELD eXcluding INR (MELD-XI) scoring system.Model for End-stage Liver Disease excluding INR (MELD-XI) score in critically ill patients: Easily available and of prognostic relevance.Cholestatic hepatic injury due to a thyroid storm: a case report from a resource limited setting.Serum Bilirubin and 6-min Walk Distance as Prognostic Predictors for Inoperable Chronic Thromboembolic Pulmonary Hypertension: A Prospective Cohort Study.Biochemical evidence of mild hepatic dysfunction identifies decompensated heart failure patients with reversible renal dysfunctionAn unusual case of cirrhosis.Novel renal biomarkers to assess cardiorenal syndromeCase report: an unrecognized etiology of transient gallbladder pain in heart failure diagnosed with internist-performed point-of-care ultrasound.Liver complications in patients with congestive heart failure.Liver diseases in heart failure.Untangling the etiology of ascitesIschemic Hepatitis as the Presenting Manifestation of Cardiac Amyloidosis.Life-threatening variceal hemorrhage in a woman with severe pulmonary arterial hypertension.Liver failure in total artificial heart therapy.Liver transplantation for acute hepatic failure.Impact of dynamic changes of elevated bilirubin on survival in patients on veno-arterial extracorporeal life support for acute circulatory failure.Hspb7 is a cardioprotective chaperone facilitating sarcomeric proteostasis.Brain death organ donor supported by a left ventricular assist device showing unexpected congestive liver fibrosis: A case report.Jaundice as a presentation of heart failure.TNM-like classification: a new proposed method for heart failure staging.Transcatheter Aortic Valve Replacement to Treat Liver Decompensation
P2860
Q26740185-21CEFA83-8DDE-4094-BE36-AF9F13B48045Q27008041-7AE16849-7F8B-4413-AA9F-DC81ECFAFE91Q28541090-37507A19-F95C-468F-A3FF-BB761B45D5D9Q33402824-30DBB17F-1BBD-4A5A-8459-E49458BB9F11Q33562258-E6904344-B2D6-4474-9B8B-3F485D2C42B6Q33657513-16BC504D-0E7C-4B2A-9693-60E5BB768F7DQ33788471-EFCA7146-6D38-4C20-ADA7-28A1CB9972F6Q33793631-EB832216-9A6B-4A62-85A3-25BF6EA6A4A9Q34211025-0A9B035A-36E6-4A69-88DA-A4BF6DDFAE53Q35001914-8DE14111-44A7-4B65-9220-DEF4A0C356F5Q35079005-29889F6C-ACD6-4C66-88E1-243075D11AACQ35684817-4DCCAE49-ADC4-4DD7-8969-3B7C70B0CFC2Q35773130-2FC63A1C-89AB-4E16-8C02-E4D769C83330Q35902564-F0A7EE95-73C9-4826-BD99-28CBFA54C9E7Q35919808-10CAD96F-3939-41A3-B62A-4FAF268EC369Q35980981-E7D73F6C-571B-4F49-BA2B-B237B67B580FQ36267363-C893A181-CE77-44E9-B4B5-C9CCE82F99A7Q36329082-719DE266-B56C-43AE-B2DF-3E26BB018150Q36694640-DDC2317A-B6F3-485D-983C-1620EA4A62F8Q37448654-37AA5CCE-36F6-4BD8-963F-C835C8542A97Q37689623-894EF0C2-34A2-4300-9713-CB98B6739B39Q38252731-90DB6067-2541-45A6-A812-07C3A683420AQ38411112-B444F29C-DC78-45D0-B5C8-04B4674C6BC2Q38633280-F973309B-37DE-4557-9998-C5AB82A76AEAQ38871702-D0B5A214-D286-4664-8F21-86F425225355Q39573219-D2C2A481-6495-4416-8BA3-E11581030D8CQ42050541-8132311B-2686-4301-866F-DEC04C0D8FB4Q42151854-6F449185-C04B-47AE-9B34-A8959F30A1B6Q42407251-CF50ADEB-5BF1-4139-AF2B-FC46509DF21AQ42793026-E608B20B-0247-4A26-B29F-617D58604C37Q47133334-0C33A627-7F01-4CC3-A7F4-11102EFDEEF3Q50055253-DE346D5B-6D7B-4761-B18F-72CFEBFD0510Q55035543-7BB5FB50-47F9-4977-B56A-D114901D27BEQ55117125-9688ADB9-80D4-40F3-956C-1F08296B0D59Q55630382-95B40677-7D76-41FB-9B90-2FDA5715C2F7Q58129981-E4F4CEFB-047F-484A-A69D-929CE5DEEE47
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The liver in heart failure
@ast
The liver in heart failure
@en
The liver in heart failure
@nl
type
label
The liver in heart failure
@ast
The liver in heart failure
@en
The liver in heart failure
@nl
prefLabel
The liver in heart failure
@ast
The liver in heart failure
@en
The liver in heart failure
@nl
P2093
P1476
The liver in heart failure
@en
P2093
Cosmas C Giallourakis
Lawrence S Friedman
Peter M Rosenberg
P304
947-67, viii-ix
P407
P577
2002-11-01T00:00:00Z